Tags

Type your tag names separated by a space and hit enter

Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset.
Elife. 2020 09 07; 9E

Abstract

Understanding and mitigating SARS-CoV-2 transmission hinges on antibody and viral RNA data that inform exposure and shedding, but extensive variation in assays, study group demographics and laboratory protocols across published studies confounds inference of true biological patterns. Our meta-analysis leverages 3214 datapoints from 516 individuals in 21 studies to reveal that seroconversion of both IgG and IgM occurs around 12 days post-symptom onset (range 1-40), with extensive individual variation that is not significantly associated with disease severity. IgG and IgM detection probabilities increase from roughly 10% at symptom onset to 98-100% by day 22, after which IgM wanes while IgG remains reliably detectable. RNA detection probability decreases from roughly 90% to zero by day 30, and is highest in feces and lower respiratory tract samples. Our findings provide a coherent evidence base for interpreting clinical diagnostics, and for the mathematical models and serological surveys that underpin public health policies.

Authors+Show Affiliations

Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States. I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium. Evolutionary Ecology Group, University of Antwerp, Antwerp, Belgium.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States.National Marine Mammal Foundation, San Diego, United States.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States. Biomathematics Department, University of California, Los Angeles, Los Angeles, United States.Ecology and Evolutionary Biology Department, University of California, Los Angeles, Los Angeles, United States.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

32894217

Citation

Borremans, Benny, et al. "Quantifying Antibody Kinetics and RNA Detection During Early-phase SARS-CoV-2 Infection By Time Since Symptom Onset." ELife, vol. 9, 2020.
Borremans B, Gamble A, Prager KC, et al. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. Elife. 2020;9.
Borremans, B., Gamble, A., Prager, K. C., Helman, S. K., McClain, A. M., Cox, C., Savage, V., & Lloyd-Smith, J. O. (2020). Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. ELife, 9. https://doi.org/10.7554/eLife.60122
Borremans B, et al. Quantifying Antibody Kinetics and RNA Detection During Early-phase SARS-CoV-2 Infection By Time Since Symptom Onset. Elife. 2020 09 7;9 PubMed PMID: 32894217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. AU - Borremans,Benny, AU - Gamble,Amandine, AU - Prager,K C, AU - Helman,Sarah K, AU - McClain,Abby M, AU - Cox,Caitlin, AU - Savage,Van, AU - Lloyd-Smith,James O, Y1 - 2020/09/07/ PY - 2020/06/17/received PY - 2020/09/04/accepted PY - 2020/9/8/pubmed PY - 2020/10/2/medline PY - 2020/9/7/entrez KW - COVID-19 KW - RNA KW - SARS-CoV-2 KW - antibody kinetics KW - detection probability KW - epidemiology KW - global health KW - human KW - meta-analysis JF - eLife JO - Elife VL - 9 N2 - Understanding and mitigating SARS-CoV-2 transmission hinges on antibody and viral RNA data that inform exposure and shedding, but extensive variation in assays, study group demographics and laboratory protocols across published studies confounds inference of true biological patterns. Our meta-analysis leverages 3214 datapoints from 516 individuals in 21 studies to reveal that seroconversion of both IgG and IgM occurs around 12 days post-symptom onset (range 1-40), with extensive individual variation that is not significantly associated with disease severity. IgG and IgM detection probabilities increase from roughly 10% at symptom onset to 98-100% by day 22, after which IgM wanes while IgG remains reliably detectable. RNA detection probability decreases from roughly 90% to zero by day 30, and is highest in feces and lower respiratory tract samples. Our findings provide a coherent evidence base for interpreting clinical diagnostics, and for the mathematical models and serological surveys that underpin public health policies. SN - 2050-084X UR - https://www.unboundmedicine.com/medline/citation/32894217/Quantifying_antibody_kinetics_and_RNA_detection_during_early_phase_SARS_CoV_2_infection_by_time_since_symptom_onset_ L2 - https://doi.org/10.7554/eLife.60122 DB - PRIME DP - Unbound Medicine ER -